Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 1/2016

01.01.2016 | Editorial

Nuclear medicine and the revolution in the modern management of castration-resistant prostate cancer patients: from 223Ra-dichloride to new horizons for therapeutic response assessment

verfasst von: Emilio Bombardieri, L. Evangelista, G. L. Ceresoli, F. Boccardo

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Excerpt

Prostate cancer (PC) is the most common neoplasm in men in Western countries, and approximately 10 – 20 % of patients with PC will develop castration-resistant disease (CRPC) [1]. More than 90 % of men with metastatic CRPC have radiological evidence of bone metastases, which are a major cause of decreased quality of life, morbidity, treatment costs and mortality [2]. CRPC is considered an incurable condition, with a median survival of less than 2 years [3]. …
Literatur
1.
Kirby M, Hirst C, Crawford ED. Characterizing the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65:1180–92.CrossRefPubMed
2.
Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006. Prostate Cancer Prostatic Dis. 2011;14:177–83.CrossRefPubMed
3.
Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, et al. Castration-resistant prostate cancer: AUA guideline. Linthicum: American Urological Association; 2014.
4.
Valdagni R, Van Poppel H, Aitchinson M, Albers P, Berthold D, Bossi A, et al. Prostate Cancer Unit Initiative in Europe: a position paper by the European School of Oncology. Clin Rev Oncol Hematol. 2015;95:133–43.CrossRef
5.
Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12:6250s–7s.CrossRefPubMed
6.
Henriksen G, Breistol K, Bruland OS, Fodstad Ø, Larsen RH. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 2002;62:3120–5.PubMed
7.
Omlin A, Pezaro C, Gillessen SS. Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. Ther Adv Urol. 2014;6:3–14.PubMedCentralCrossRefPubMed
8.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.CrossRefPubMed
9.
Nilsson S. Alpha-emitter radium-223 in the management of solid tumors: current status and future directions. Am Soc Clin Oncol Educ Book. 2014;34:e132–9.CrossRef
10.
Carrasquillo JA, O’Donoghue JA, Pandit-Taskar N, Humm JL, Rathkopf DE, Slovin SF, et al. Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40:1384–93.CrossRefPubMed
11.
Harrison GE, Carr TE, Sutton A, Rundo J. Plasma concentration and excretion of calcium-47, strontium-85, barium-133 and radium-223 following successive intravenous doses to a healthy man. Nature. 1966;209:526–7.CrossRefPubMed
12.
Nilsson S, Larsen RH, Fosså SD, Balteskard L, Borch KW, Westlin JE, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11:4451–9.CrossRefPubMed
13.
Graff JN, Beer TM. Pharmacotherapeutic management of metastatic castration resistant prostate cancer in the elderly; focus on non-chemotherapy agents. Drugs Aging. 2014;31:873–82.PubMedCentralCrossRefPubMed
14.
Nilsson S. Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety. Expert Opin Drug Saf. 2015;14:1127–36.CrossRefPubMed
15.
Vogelzang N, Helle S, Johannessen D, O'Sullivan JM, Garcia-Vargas JE, O'Bryan-Tear CG, et al. Efficacy and safety of radium-223 dichloride in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel in the phase III ALSYMPCA trial. J Clin Oncol. 2013;31(Suppl):abstract 5068.
16.
Michalski JM, Parker C, Sartor O, Vogelzang N, Haugen I, Wahba M, et al. Impact of prior docetaxel, extent of disease, and prior bisphosphonates on hematologic safety of radium-223 dichloride from ALSYMPCA. Int J Radiat Oncol. 2014;90 Suppl 1:S441–2.CrossRef
17.
Parker C, Vogelzang N, Sartor O, Coleman RE, Fang F, Skjorestad I, et al. 3-year safety follow-up of radium-223 dichloride in patients with castration resistant prostate cancer and symptomatic bone metastases from ALSYMPCA. J Clin Oncol. 2015;33(Suppl 7):abstract 195.
18.
Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014;32:3436–48.CrossRefPubMed
19.
20.
Dan TD, Eldredge-Hindy HB, Hoffman-Censits J, Lin J, Kelly WK, Gomella LG, et al. Hematologic toxicity of concurrent administration of radium-223 and next-generation antiandrogen therapies. Am J Clin Oncol. 2015. doi:10.​1097/​COC.​0000000000000181​ PubMed
21.
Sartor O, Fernandez D, Morris M, Iagaru A, Brown A, Almeida F, et al. Prior and concurrent use of abiraterone and enzalutamide with radium-223 in an expanded access setting. J Clin Oncol. 2015;33(Suppl 7): abstract 253.
22.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed
23.
Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015;26:1589–604.PubMedCentralCrossRefPubMed
24.
Sher HI, Morris MJ, Stadler WM, Higano CS, Halabi S, Smith MR, et al. The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). J Clin Oncol. 2015;33(Suppl):abstract 5000.
25.
National Comprehensive Cancer Network (NCCN version 1.2015), available form the following link: www.​nccn.​org.
Metadaten
Titel
Nuclear medicine and the revolution in the modern management of castration-resistant prostate cancer patients: from 223Ra-dichloride to new horizons for therapeutic response assessment
verfasst von
Emilio Bombardieri
L. Evangelista
G. L. Ceresoli
F. Boccardo
Publikationsdatum
01.01.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-015-3189-0

Weitere Artikel der Ausgabe 1/2016

European Journal of Nuclear Medicine and Molecular Imaging 1/2016 Zur Ausgabe

Image of the Month

Paget bone disease demonstrated on 68Ga-PSMA ligand PET/CT

Original Article

Imaging malignant melanoma with 18F-5-FPN

Original Article

11C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel

Letter to the Editor

Prostate-specific antigen and radiolabelled choline PET/CT for the assessment of response to therapy: synergy or conflicting?

Original Article

Test–retest reproducibility of [11C]PBR28 binding to TSPO in healthy control subjects

Image of the Month

Intense PSMA-expression using 68Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis